BioSpace News Archive

In the latest results shared by the company, treatment with nusinersen for a median of 4.9 years helped participants maintain and make progressive gains in motor function.

BioSpace talked with Paul Mango, one of the key leaders of Operation Warp Speed, about the experience.

Incyte Corporation reported that the FDA has pushed back the review of the company’s supplemental New Drug Application (sNDA) for Opzelura (ruxolitinib cream) for vitiligo.

DUBAI, United Arab Emirates, During the projected period, the global demand for Telehealth And Telemedicine Market is predicted to develop at a CAGR of 26.6 percent, reaching US$ 285.7 billion by 2027, up from an estimated US$ 87.8 billion in 2022.

Albany NY, United States: The consolidated competitors landscape of global surgical sutures market is set witness a decent CAGR over the forecast period of 2017-2025, creating opportunities for market players worth USD 5 billion.

Endoscopic mucosal resection and endoscopic submucosal dissection, are most common type of Endoscopic resection techniques, which is aided by injection of submucosal lifting agents to expand the submucosal area, untangles polypectomy and reduces the chances of adverse effects.

InDex Pharmaceuticals Holding AB is planning for self-commercialisation of the drug candidate cobitolimod in the US with strategic collaborations in other regions.

IDEAYA Biosciences, Inc. announced that it has entered into additional clinical trial collaboration and supply agreements with Pfizer Inc. to support further evaluation of darovasertib and crizotinib combination therapy in a Phase 2 potential registration-enabling clinical trial in patients with metastatic uveal melanoma and in a Phase 1 clinical trial in patients with cMET-driven tumors, such as hepatocellular carcinoma and/or non-small cell lung cancer.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced its financial and operating results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

Shoulder Innovations Inc. announces the FDA Clearance of their latest component of the InSet™ Total Shoulder System, the InSet™ Stemless Humeral System.